share_log

B of A Securities Maintains Buy on Neumora Therapeutics, Lowers Price Target to $7

Benzinga ·  Jan 6 19:42  · Ratings

B of A Securities analyst Geoff Meacham maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and lowers the price target from $22 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment